Hodgkin’s lymphoma – an update
Keywords:
Hodgkin’s lymphoma, chemotherapy, radiotherapyAbstract
There has been a tremendous change in the management of Hodgkin’s Lymphoma since it was first
described in 1832 by Thomas Hodgkin. It may be
considered one of the non-cutaneous malignancies
with higher rates of cure. In this article, an updated review of the pathophysiology, classification,
pathology, treatment and prognosis of Hodgkin’s
Lymphoma is presented
Downloads
References
Horning SJ: Hodgkin Lymphoma. In: Beutler E, Litchman MA, Coller BS et al. (eds): Williams Hematology 6th ed. New York, McGraw-Hill
:1215-1235.
Parkin DM, Muir CS, Whelan et al. Cancer Incidence in Five Continents, Vol. VI. Lyon: International Agency for Research on Cancer
Armitage JO, Longo DL: Malignancies of Lymphoid Cells. In. Braunwald E, Hauser SL, Fauci A et al (eds): Harrison’s Principles of
Internal Medicine 15th ed. New York, McGraw-Hill 2001: 715-727.
Pileri SA, Ascari S, Leoncini L et al. Hodgkin’s Lymphoma: the pathologit’s viewpoint. J Clin Pathol 2002; 55: 162-176.
Harris NL. Hodgkin’s Lymphoma: classification, diagnosis and grading. Semin Hematol 1999; 36: 220-232.
Yung L, Linch D. Hodgkin’s Lymphoma. The Lancet 2003; 361: 943-951.
Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and Etiology of Hodgkin’s Lymphoma. European Society for Medical
Oncology 2002; 147-151.
Goedert JJ, Coté TR, Virgo P et al. for the AIDS-cancer match study group. Spectrum of AIDS-associated malignant disorders. Lancet 1998;
: 1833-1839.
Marafiote T, Himmel M, Foss HD etal. Hodgkin and Reed-stenberg cells represent an expansion of a single clone originating from a germinal
center B-cell with functional immunoglobulin gene rearrangement but defective immunoglobulin transcription. Blood 2000; 99: 1443-
Thomas RK, Kallenborn A, Wickenhauser C et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol
; 160: 1521-1528.
Kaplan HS. Hodgkin Disease. Harvard University Press, Cambridge, MA; 1980.
Tubiana M, Attie E, Flamant R, Gerard MR, Hayat M. Prognostic factors in 454 cases of Hodgkin’s disease. Cancer Res 1971; 31: 1801.
Atkinson K, Austin DE, McElwain TJ, Peckham MJ. Alcohol pain in Hodgkin’s disease. Cancer 1976; 37: 895.
MacLennan KA, Hudson BV, Jelliffe AM, Haybittle JL, Hudson GV. The pretreatment peripheral blood lymphocyte count in 1100 patients
with Hodgkin’s disease: the prognostic significance and the relationship to the presence of systemic symptoms. Clin Oncol 1981; 7: 333.
MacLennan KA, Vaughan HB, Easterling MJ, Jelliffe AM, Vaughan HG, Haybittle JL. The presentation haemoglobin level in 1103 patients
with Hodgkin’s disease. Clin Radiol 1983; 34: 311.
Simmons AV, Spiers AS, Fayers PM. Haematological and clinical parameters in assessing activity in Hodgkin’s disease and other malignant
lymphomas. Q J Med 1973; 42: 111.
Ultmann JE, Cunningham JK, Gellhorn A. The clinical picture of Hodgkin’s disease. Cancer Res 1966; 26: 1047.
Horwitz SM, Hornig SJ. Advances in the treatment of Hodgkin’s Lymphoma. Current Opinion in Hematology 2000; 7: 235-240.
Aisenberg AC, Kaplan MM, Rieder SV. Serum alkaline phosphatase at the onset of Hodgkin’s Disease. Cancer 1970; 26: 318.
Mercier RJ, Thompson JM, Harman GC, Messerschmidt GL. Recurrent hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in
Hodgkin’s disease. Am J Med 1988; 84: 165.
Braund WJ, Naylor BA, Williamson DH et al. Autoimunity to insulin receptor and hypoglicaemia in patients with Hodgkin’s disease. The
Lancet 1987; 1: 237.
Cancer Management Guidelines of the BC Cancer Agency, Care & Research, 2002.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998; 339: 1506-1514.
Dimopoulos MA, Cabanillas F, Lee JJ et al. Prognostic role of serum beta 2-microglobulin in Hodgkin’s disease. J Clin Oncol 1993; 11:
Canellos GP. Primary treatment of Hodgkin’s disease. European Society for Medical Oncology 2002; 153-158.
Sarris AH, Kliche KO, Pethambaram P et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin’s disease and are
associated with inferior failure-free survival. Ann Oncol 1999; 10: 433-440.
Schulz H, Rehwald U, Reiser M, Diehl V, Engert A, on behalf of the German Hodgkin Lymphoma Study Group. The monoclonal antibody
rituximab is well tolerated and extremely effective in the treatment of relapsed CD-20 positive Hodgkin’s Lymphoma: an update. Ann Oncol
; 13: 63.
Aleman B, Raemaeken J, Tirelli U et al. Involved-Field Radiotherapy for advanced Hodgkin’s Lymphoma. N Engl J Med 2003; 348 (24):
-2406.
Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with
ABVD. N Engl J Med 1992; 327: 1478-1484.
Duggan D, Petroni G, Johnson J et al. MOPP/ABV versus ABVD for advanced Hodgkin’s disease: a preliminary report of CALGB 8952
(with SWSOG, ECOG, NCIC). Proc Am Soc Clin Oncol 1997; 16: 12.
Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results
of a prospective clinical trial. J Clin Oncol 2002; 20: 630-637.
Diehl V, Franklin J, Paulus U et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin’s disease: final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood 2001; 98: 769.
Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced
Hodgkin’s disease. N Engl J Med 2003; 348 (24): 2386-2395.
Horning S. Hodgkin’s disease. In Cavalli F, Hansen HH, Kaye S. Textbook of Medical Oncology, 2nd edition. London: Martin Dunitz
Publishers 2000; 461-474.
Cavalli FG. Hodgkin’s disease: treatment of relapsed disease. European Society for Medical Oncology 2002; 13: 159-162.
Majolino I, Pearce R, Taghipour G, Goldstone AH. Peripheral blood stem cell transplantation versus autologous bone marrow transplantation in Hodgkin’s and non- Hodgkin’s Lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. J Clin Oncol 1997; 15: 509-517.
Wirth A, Corry J, Laidlaw C et al. Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Phys
; 39: 599-607.
Swerdlow AJ, Schoemaker MJ, Allerton R et al. Lung cancer after Hodgkin’s disease: a nested case control study of the relation to treatment. J Clin Oncol 2001; 19: 1610-1618.
Swerdlow AJ, Barber JA, Hudson GV et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation
to age of treatment. J Clin Oncol 2000; 18: 498-509.
Hancock SL, Tucker MA; Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993;
: 1949-1955.
Rooney CM, Bollard C, Huls MH et al. Immunotherapy for Hodgkin’s disease. Ann Hematol 2002; 81 (2): S39-S42.
Barth S, Huhn M, Matthey B et al. Ki-4(scFV)-ETA’, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity
against disseminated Hodgkin tumours in SCID mice. Blood 2000; 95: 3909-3914.
Scnell R, Dietlein M, Schomaker K et al. Non-myeloablative radioimmunotherapy with an iodine-131 tagged anti-CD30 antibody in patients
with Hodgkin’s Lymphoma. Ann Oncol 2002; 13 (2): 86.
Engert A, Gottstein C, Bohlen H et al. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Reed-Sternberg
cells have superior anti-tumour effects agains H-RS cells in vivo and solid Hodgkin tumours in mice. Int J Cancer 1995; 63: 304-309.
Renner C, Bauer S, Sahin U et al. Cure of disseminates xenografted human Hodgkin’s tumours by biespecific monoclonal antibodies and
human T cells: the role of T cells subsets in a preclinical model. Blood1996; 87: 2930-2937
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
